Multiple brokerages have issued buy recommendations on Rainbow Children's Medicare with target prices ranging from ₹1,550 to ₹1,600 per share. According to latest reports, Prabhudas Lilladher has issued a 'BUY' rating with a target price of ₹1,550 per share, while Anand Rathi has recommended a target price of ₹1,600 in its research report dated January 30, 2026. The consensus among brokerages reflects strong confidence in the company's fundamentals and growth prospects in the pediatric healthcare sector.
The company's Q3FY26 EBITDA grew by 9% year-on-year, which was largely in line with expectations. As reported by Prabhudas Lilladher, Rainbow Children's Medicare has added approximately 780 beds over the past two years, effectively concluding its current expansion cycle. The broker noted that overall profitability is expected to improve from FY27 with 18% EBITDA CAGR over FY26-28E versus 10% CAGR over FY24-26E as new capacities ramp up.
The company enjoys several competitive advantages that support its growth trajectory. According to the broker's analysis, Rainbow Children's Medicare operates an asset-light hub-and-spoke model with strong free cash flow generation and net cash balance sheet. The company is positioned as the only integrated multi-specialty pediatric hospital chain in India offering comprehensive services, with a full-time doctor engagement model. Strategic expansion across its core markets in South India is expected to drive sustainable growth.
The broker's FY27E and FY28E EBITDA estimates remain broadly unchanged from previous projections. As reported by Prabhudas Lilladher, the company's strong fundamentals include higher margins, robust free cash flow generation, and healthy return ratios due to its operational model. The company's positioning as the only integrated pediatric hospital chain in India, combined with its strategic expansion plans, supports the positive outlook for sustained growth across multiple brokerage recommendations.
